Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5.F35-GUCY2C-PADRE
- Development stage
- Phase 2
- Lead developer
- Thomas Jefferson University
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad5.F35-GUCY2C-PADRE is a recombinant cancer vaccine designed to prevent recurrence in patients with gastrointestinal (GI) adenocarcinomas following definitive surgery and adjuvant therapies. The vaccine uses a chimeric viral vector composed of an adenovirus serotype 5 (Ad5) capsid and an adenovirus serotype 35 (Ad35) fiber protein, which reduces sensitivity to pre-existing immunity against Ad5. It encodes the extracellular domain of guanylyl cyclase C (GUCY2C), a protein overexpressed in GI cancers but compartmentalized in normal intestinal cells, making it an attractive immunotherapy target. The construct also includes PADRE, a universal CD4+ T-helper epitope that enhances immune response. Upon intramuscular administration, the vector targets CD46 on tumor cells for uptake and induces anti-tumor immunity by presenting GUCY2C antigens to the immune system[1][3][4][8].
- Other names
- adenovirus 5/F35-human guanylyl cyclase C-PADRE
02
Targets
CD46 (CD46 Molecule)GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on Ad5.F35-GUCY2C-PADRE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad5.F35-GUCY2C-PADRE.